UB151
ProductEpalrestat Tablets
Strength50mg
IndicationsDiabetic peripheral neuropathy; Otitis media; Bronchitis; Pneumonia; Respiratory tract infection; Urinary tract infection; Skin and soft tissue infection; Bone infection; Joint infection; Septicaemia; Endocarditis infective; Hepatobiliary infection; Eye infection; Ear infection; Nasal infection; Throat infection; Surgical prophylaxis
TherapeuticsMetabolic & Endocrinology
GMPCN - NMPA
RegistrationChina
ModalitiesSmall Molecule
Exclusive Summary
- • Off-patent and absent from US/EU; many Asia/MENA/LATAM markets remain whitespace for first/only entrants.
- • DPN affects an estimated 160–270 million people globally, driving steady long-term demand.
- • Listed in Japanese and Chinese guidelines as a disease-modifying option for early DPN, complementary to analgesics.
- • JP-compliant API with Technology Transfer and Distribution models enables faster registration in JP-accepting markets (Vietnam requires a direct local partner).
- • Generics typically offer 50–80% price cuts vs. originator, supporting reimbursement and rapid uptake.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →